Abbott Laboratories Receives FDA Approval and CE Mark for Ultreon 3.0 Software

Abbott Laboratories announced that it has received U.S. Food and Drug Administration (FDA) approval and a CE mark in Europe for its next-generation Ultreon 3.0 software. This software stands out as a technology used in the imaging and treatment of coronary artery diseases. The company stated that following these approvals, the software will be made available in the global market. The Ultreon 3.0 software is integrated into the intravascular optical coherence tomography (OCT) imaging system, providing doctors with more detailed, three-dimensional analysis of intravascular structures. Abbott noted that this technology aims to improve patient outcomes by increasing precision in stent placement procedures. The FDA approval and CE mark confirm that the software meets safety and efficacy standards. With this development, Abbott aims to strengthen its leadership position in the cardiovascular imaging field. The company emphasized that the software will be a particularly important tool in evaluating complex coronary lesions. This is not investment advice.